Please enter exact key words
First-in-class Antibody Therapeutics Targeting Frizzled 8 Receptor

for the Treatment of Solid Tumors

Home / Available Projects / First-in-class Antibody Therapeutics Targeting Frizzled 8 Receptor
Drug Name GPCR-targeted Project 015

A first-in-class recombinant antibody targeting Frizzled 8 (Fzd8) receptor is being developed for the treatment of solid tumors. It is expected that the candidate may be developed in combination with standard chemotherapy and targeted therapy.

Target Frizzled 8 (FZD8)
Drug Modality Monoclonal antibody
Indication Solid tumors
Product Category Biologic
Mechanism of Action Frizzled 8 modulators
Status Discovery
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.